These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
397 related articles for article (PubMed ID: 30559105)
1. Effects of Molidustat in the Treatment of Anemia in CKD. Macdougall IC; Akizawa T; Berns JS; Bernhardt T; Krueger T Clin J Am Soc Nephrol; 2019 Jan; 14(1):28-39. PubMed ID: 30559105 [TBL] [Abstract][Full Text] [Related]
2. Long-Term Efficacy and Safety of Molidustat for Anemia in Chronic Kidney Disease: DIALOGUE Extension Studies. Akizawa T; Macdougall IC; Berns JS; Bernhardt T; Staedtler G; Taguchi M; Iekushi K; Krueger T Am J Nephrol; 2019; 49(4):271-280. PubMed ID: 30852574 [TBL] [Abstract][Full Text] [Related]
3. Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study. Yamamoto H; Nobori K; Matsuda Y; Hayashi Y; Hayasaki T; Akizawa T Am J Nephrol; 2021; 52(10-11):884-893. PubMed ID: 34569482 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial. Yamamoto H; Nobori K; Matsuda Y; Hayashi Y; Hayasaki T; Akizawa T Am J Nephrol; 2021; 52(10-11):871-883. PubMed ID: 34569489 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis. Zheng Q; Yang H; Sun L; Wei R; Fu X; Wang Y; Huang Y; Liu YN; Liu WJ Pharmacol Res; 2020 Sep; 159():105020. PubMed ID: 32561478 [TBL] [Abstract][Full Text] [Related]
6. Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies. Yamamoto H; Taguchi M; Matsuda Y; Iekushi K; Yamada T; Akizawa T BMJ Open; 2019 Jun; 9(6):e026704. PubMed ID: 31203242 [TBL] [Abstract][Full Text] [Related]
7. Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: design and rationale of three phase III studies. Akizawa T; Taguchi M; Matsuda Y; Iekushi K; Yamada T; Yamamoto H BMJ Open; 2019 Jun; 9(6):e026602. PubMed ID: 31203241 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia: A Randomized, Double-Blind, Phase 3 Trial. Akizawa T; Nangaku M; Yonekawa T; Okuda N; Kawamatsu S; Onoue T; Endo Y; Hara K; Cobitz AR Clin J Am Soc Nephrol; 2020 Aug; 15(8):1155-1165. PubMed ID: 32723804 [TBL] [Abstract][Full Text] [Related]
9. Iron Regulation by Molidustat, a Daily Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, in Patients with Chronic Kidney Disease. Akizawa T; Macdougall IC; Berns JS; Yamamoto H; Taguchi M; Iekushi K; Bernhardt T Nephron; 2019; 143(4):243-254. PubMed ID: 31387097 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and Long-Term Safety of C.E.R.A. Maintenance in Pediatric Hemodialysis Patients with Anemia of CKD. Fischbach M; Wühl E; Reigner SCM; Morgan Z; Schaefer F Clin J Am Soc Nephrol; 2018 Jan; 13(1):81-90. PubMed ID: 29097481 [TBL] [Abstract][Full Text] [Related]
11. Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan. Akizawa T; Iwasaki M; Yamaguchi Y; Majikawa Y; Reusch M J Am Soc Nephrol; 2020 Jul; 31(7):1628-1639. PubMed ID: 32493693 [TBL] [Abstract][Full Text] [Related]
12. Subcutaneous C.E.R.A. for the Maintenance Treatment of Anemia in Pediatric Patients With CKD: A Phase 2, Open-Label, Single-Arm, Multicenter Study. Warady BA; Meyer Reigner S; Tirodkar C; Drozdz D Am J Kidney Dis; 2023 Jun; 81(6):684-694.e1. PubMed ID: 36587890 [TBL] [Abstract][Full Text] [Related]
13. Treatment satisfaction with molidustat in CKD-related anemia in non-dialysis patients: a post-hoc analysis of two clinical trials. Yamamoto H; Yamada T; Miyazaki K; Yamashita T; Kato T; Ohara K; Nakamura Y; Akizawa T Clin Exp Nephrol; 2023 Aug; 27(8):651-659. PubMed ID: 37095342 [TBL] [Abstract][Full Text] [Related]
14. Effects of three kinds of erythropoiesis-stimulating agents on renal anemia in Japanese non-dialysis chronic kidney disease patients. Kuwahara M; Hasumi S; Mandai S; Tanaka T; Shikuma S; Akita W; Mori Y; Sasaki S Clin Exp Nephrol; 2014 Oct; 18(5):755-62. PubMed ID: 24317507 [TBL] [Abstract][Full Text] [Related]